WEIQIN XU: Open Payments
NPI 1154839058 · ROSEMEAD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$8,384 in 287 payments from 50 companies in 2025. Trend: 2023 $9,298 · 2024 $10,464 · 2025 $8,384
Food & beverage: $7,057Long term medical supply or device loan: $1,000Education: $327
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 26 | $1,350 |
| Janssen Biotech, Inc. | 35 | $1,098 |
| AstraZeneca Pharmaceuticals LP | 29 | $1,002 |
| BeOne Medicines USA, Inc. | 10 | $346 |
| Incyte Corporation | 16 | $275 |
| PFIZER INC. | 15 | $274 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $271 |
| Merck Sharp & Dohme LLC | 10 | $235 |
| ABBVIE INC. | 8 | $230 |
| E.R. Squibb & Sons, L.L.C. | 6 | $228 |
Products named: KISQALI, RYBREVANT, ERLEADA, BRUKINSA, Nubeqa, ENHERTU, IMFINZI, DARZALEX.
Industry payments across CA — which companies pay providers there.
